J Thromb Haemost: Relationship between platelet reduction and mortality in patients with COVID-19

Acute coronavirus 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome (SARS-CoV-2) is spreading rapidly worldwidePlatelet reduction in patients with COVID-19 has not been fully analyzedRecently, the journal Of Thrombosis and Haemostasis, an authoritative journal of thrombosis and clotting disease, published a study that described platelet reduction in patients with COVID-19researchers retrospectively collected the lowest platelet count seither during hospitalization of 1476 consecutive patients at Jinyintan Hospital in Wuhan City, and divided them into groups of (0-50,50,100, (100-150) or (150-) x 109/L), and analyzed the lowest platelet count and in-hospital mortality rates238 (16.1%) had a decrease in platelet sizedness in all patients and 306 (20.7%) had platelet reductionNon-survivors are older than survivors, have a lower incidence of platelet reduction and have lower minimum platelet countsIn-hospital mortality rates were 92.1%, 61.2%, 17.5% and 4.7% for patients in the (0-50-100), (100-150) and (150-) groups, respectivelyIn contrast to the (150-) group, the lowest platelet counts were (100-150), (50-100) and (0-50) patients with a relative risk of 3.42 (95% CI) was 3.42 (95% CI) 2.36-4.96), 9.99 (95% CI 7.16-13.94) and 13.68 (95% CI is 9.89-18.92)it is clear that platelet reduction is common in patients with COVID-19 and is associated with an increased risk of death in the hospitalThe fewer platelets in patients with COVID-19, the higher the mortality rate